CELMoDs on the Horizon: A New Chapter in Lymphoma Care

Treatment options for patients with lymphoma are rapidly evolving. In this podcast episode, Alex F. Herrera, MD, and Marc Hoffmann, MD, discuss cereblon E3 ligase modulators (CELMoDs) as potential treatment options for patients with aggressive diffuse large B-cell lymphoma and follicular lymphoma, with a focus on golcadomide, an investigational, oral, first-in-class CELMoD therapy. Topic areas covered include: 

Biologic and clinical rationale for the use of CELMoD therapy in lymphoma patients Emerging clinical trial data on golcadomide alone and in combination with other regimens Real-world expectations for incorporating CELMoD-based therapies into community lymphoma care settings such as efficacy, patient selection, and toxicity management strategies

Presenters:

Alex F. Herrera, MD
Chief, Division of Lymphoma
Professor, Department of Hematology and Hematopoietic Cell Transplantation
Director, Toni Stephenson Lymphoma Center
City of Hope
Duarte, California

Marc Hoffmann, MD
Director, Lymphoma Program
Medical Director, Lean and Quality Improvement
Associate Professor
Division of Hematologic Malignancies and Cellular Therapeutics
University of Kansas Cancer Center
Kansas City, Kansas

Content based on an online CME program supported by an educational grant from Bristol Myers Squibb.

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Link to CME: Claim Credit

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.